After years of promises, industrial biotechnology stands at a pivotal juncture, where its potential can only be realized through deliberate and strategic actions.

The Bioyard is our platform for industrial-scale precision fermentation. Traditional biomanufacturing sites are often built around bio-pharma and around legacy infrastructure, which can be rigid, costly, and difficult to optimize. At Arsenale, we wanted to take a different approach.

A Pordenone c'è Arsenale Bioyards, una startup che vuole ridurre i costi di un processo per ottenere da lieviti e funghi alternative bio al petrolchimico

This conversation is a masterclass in turning big vision into executable industrial strategy, and a rare peek into how deeptech founders can blend science, storytelling, and stoic leadership to win over top-tier VCs.

Scaling precision fermentation isn’t just about engineering microbes—it’s about building a biomanufacturing ecosystem that works at scale.

For the very first time, industry leaders and biotech startups have come together to form the AB4S Advanced Biotech for Sustainability Coalition.

In a recent interview with Sky TG24, Arsenale CEO and Co-Founder, Massimo Portincaso explores a critical question: Can Italy become the hub of global biomanufacturing? We believe the answer is yes. And not only yes — urgently yes.

For decades, industrial biotech has borrowed its manufacturing playbook from biopharma—and it’s been a costly mistake.

A Bessemer Moment for Biomanufacturing?
Explore how Arsenale Bioyards are shattering cost barriers in precision fermentation—driving a paradigm shift in industrial biotech.

L’azienda di Pordenone ha appena concluso un aumento di capitale per 10 milioni di euro, guidato da Cdp. Con la sua piattaforma end to end riprogramma geneticamente batteri e lieviti per trasformarli in strumenti di produzione di insulina, lattoferrina, collegene.

Arsenale Bioyards, azienda che vuole trasformare il mercate del bio-manufacturing, ha annunciato la chiusura del suo primo round di investimento seed da 10 milioni di euro

A proprietary, AI-driven end-to-end platform making biomanufacturing at scale economically viable – for the very first time

Massimo Portincaso: Pioneering Bio Manufacturing (Star Trek is Here?)

We caught up with Massimo Portincaso, the entrepreneur behind fledgling bio-manufacturing startup Arsenale.

On August 9th, 2023, the synthetic biology pioneer Amyris announced its voluntary filing for Chapter 11/Bankruptcy. I think this is a very important moment for the industry as it officially sanctions the end of an era, and (I hope) the beginning of a new one for the industry, and more in general for the transition of our industrial backbone from an exploitative to generative paradigm.

Not so long ago, the technology startup landscape in Europe was sparsely populated, especially when compared with other tech-rich regions of the world.

Corporates are sitting on a wealth of resources (not only financial) that could help European deeptech companies scale

Despite investment growing to more than $60 billion in 2020 and its massive disruption potential as the Fourth Wave of Innovation, deep tech is hindered by the current investment model.

The fourth industrial revolution, (…). But much less publicized, and yet much more disruptive, is the other side of this fourth industrial era - that of nature co-design.

There’s another industrial revolution forming, and it promises to be at least as far reaching as the ones before it.